Ansa Biotechnologies

ansabio.com →

-4%

est. 2Y upside i

HealthcareSeries B

Next-generation DNA synthesis using enzymes

Rank

#2384

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

The equity upside is highly uncertain due to missing revenue data and high incumbent threat.

Last updated: July 3, 2026

Bull (10%)+280%

Strong adoption of enzymatic DNA synthesis leads to rapid revenue growth and market leadership. Exit multiple expands to 6x forward revenue, valuing the company at ~$800M, a 3x return before dilution.

Base (45%)+30%

Gradual revenue growth with moderate market share gains. Exit multiple converges to 4x forward revenue, resulting in a 50% return before dilution, net 30% after dilution.

Bear (45%)-100%

Incumbents dominate and revenue fails to materialize. Exit value below $177M preference stack, common stock recovers nothing.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

68%

Total preferred liquidation preference of $177M represents 68% of current valuation, meaning common stock is deeply subordinated.

Dilution Risk

high

With $177M raised and high burn, additional financing within 24 months is likely, diluting common equity by 15-25%.

Secondary Liquidity

none

No secondary market activity reported.

View all 6 open roles at Ansa Biotechnologies →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Ansa Biotechnologies's data — designed to show you've done your homework.

  • 1

    “How does Ansa's cost per base compare to chemical synthesis and what is the roadmap to cost parity?”

  • 2

    “What is the current revenue run rate and growth trajectory?”

  • 3

    “What is the expected dilution for common shareholders in the next financing round?”

Community

Valuation Sentiment

Our model estimates -4% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.